Advertisement

Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients

      Atherosclerosis is increasingly recognized as a complex phenomenon involving the interaction of several mechanisms. Dyslipidemia, thrombosis, and other metabolic dysfunctional syndromes have been implicated in atherogenesis and its secondary complications.
      • Oparil S.
      • Oberman A.
      Nontraditional cardiovascular risk factors.
      More recently, inflammation has been proposed to play an important role in the pathophysiology of atherosclerosis and to be an important determinant of plaque vulnerability.
      • Ross R.
      Atherosclerosis—an inflammatory disease.
      Although thrombosis, dyslipidemia, and proinflammatory conditions contribute to atherosclerosis and increased risk of cardiac events, the associations among these 3 pathologic states are not well understood. Therefore, the aim of this study was to evaluate the relations among inflammation, thrombosis, and dyslipidemia, by comparing the levels of their respective serum markers measured in a population of patients in a stable phase after myocardial infarction.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Oparil S.
        • Oberman A.
        Nontraditional cardiovascular risk factors.
        Am J Med Sci. 1999; 317: 193-207
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Moss A.J.
        • Goldstein R.E.
        • Marder V.J.
        • Sparks C.E.
        • Oakes D.
        • Greenberg H.
        • Weiss H.J.
        • Zareba W.
        • Brown M.W.
        • Liang C.S.
        • et al.
        Thrombogenic factors and recurrent coronary events.
        Circulation. 1999; 99: 2517-2522
        • Rifai N.
        • Tracy R.P.
        • Ridker P.M.
        Clinical efficacy of an automated high-sensitivity C-reactive protein assay.
        Clin Chem. 1999; 45: 2136-2141
        • Rohde L.E.
        • Hennekens C.H.
        • Ridker P.M.
        Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.
        Am J Cardiol. 1999; 84: 1018-1022
        • Mendall M.A.
        • Patel P.
        • Ballam L.
        • Strachan D.
        • Northfield T.C.
        C reactive protein and its relation to cardiovascular risk factors.
        BMJ. 1996; 312: 1061-1065
        • St-Pierre A.C.
        • Ruel I.L.
        • Cantin B.
        • Dagenais G.R.
        • Bernard P.M.
        • Despres J.P.
        • Lamarche B.
        Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease.
        Circulation. 2001; 104: 2295-2299
        • Holvoet P.
        • Mertens A.
        • Verhamme P.
        • Bogaerts K.
        • Beyens G.
        • Verhaeghe R.
        • Collen D.
        • Muls E.
        • Van de Werf F.
        Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2001; 21: 844-848
        • Koenig W.
        • Rothenbacher D.
        • Hoffmeister A.
        • Griesshammer M.
        • Brenner H.
        Plasma fibrin D-dimer levels and risk of stable coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1701-1705
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.A.
        • Sacks F.M.
        • Moye L.A.
        • Goldman S.
        • Flaker G.C.
        • Braunwald E.
        Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
        Circulation. 1998; 98: 839-844